Chimeric Therapeutics is trading at A$0.01 (+16.67%), with the gain appearing consistent with low-liquidity trading rather than a verified catalyst.
- No confirmed company announcement dated September 15 or September 16, 2026 was identified.
- The latest major update, dated August 19, 2026, concerned halted CHM-2101 trial enrolment after dose-limiting toxicities, but does not directly explain the movement.
- Broader biotech weakness also does not explain the upward move.